A detailed history of Los Angeles Capital Management LLC transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Los Angeles Capital Management LLC holds 26,544 shares of NRIX stock, worth $712,971. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,544
Previous 33,245 20.16%
Holding current value
$712,971
Previous $693,000 14.14%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

SELL
$18.93 - $25.69 $126,849 - $172,148
-6,701 Reduced 20.16%
26,544 $595,000
Q2 2024

Aug 05, 2024

SELL
$12.02 - $21.3 $830,293 - $1.47 Million
-69,076 Reduced 67.51%
33,245 $693,000
Q1 2024

Apr 05, 2024

SELL
$7.77 - $15.66 $183,993 - $370,828
-23,680 Reduced 18.79%
102,321 $1.5 Million
Q4 2023

Feb 06, 2024

BUY
$4.25 - $10.71 $688 - $1,735
162 Added 0.13%
126,001 $1.3 Million
Q3 2023

Nov 06, 2023

BUY
$7.86 - $10.08 $133,533 - $171,249
16,989 Added 15.61%
125,839 $989,000
Q2 2023

Aug 03, 2023

BUY
$8.7 - $13.28 $44,117 - $67,342
5,071 Added 4.89%
108,850 $1.09 Million
Q1 2023

May 04, 2023

SELL
$8.56 - $13.26 $23,112 - $35,802
-2,700 Reduced 2.54%
103,779 $921,000
Q4 2022

Feb 06, 2023

BUY
$9.86 - $14.59 $382,804 - $566,442
38,824 Added 57.39%
106,479 $1.17 Million
Q3 2022

Nov 02, 2022

BUY
$12.33 - $19.81 $670,628 - $1.08 Million
54,390 Added 410.03%
67,655 $882,000
Q2 2022

Aug 05, 2022

BUY
$7.88 - $14.82 $2,048 - $3,853
260 Added 2.0%
13,265 $168,000
Q4 2021

Feb 03, 2022

BUY
$26.43 - $34.5 $343,722 - $448,672
13,005 New
13,005 $376,000

Others Institutions Holding NRIX

About Nurix Therapeutics, Inc.


  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $1.27B
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track This Portfolio

Track Los Angeles Capital Management LLC Portfolio

Follow Los Angeles Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.